Skip to main content

Table 2 Renin-angiotensin-aldosterone system inhibitor use at baseline, relative to target maintenance doses recommended by European Society of Cardiology guidelines for heart failure management [9]

From: Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink

RAASi agent

Number of patients

RAASi dosing at baseline, n (%)a

≥100% of target

50% to < 100% of target

< 50% of target

ACE inhibitorsb

53,571

19,345 (36.11%)

14,202 (26.51%)

20,024 (37.38%)

ARBsc

18,671

613 (3.28%)

6953 (37.24%)

11,105 (59.48%)

MRAsd

3770

1358 (36.02%)

2412 (63.98%)

0 (0.00%)

  1. ACE angiotensin converting enzyme, ARBs angiotensin receptor blockers, MRAs mineralocorticoid receptor antagonist, RAASi renin-angiotensin-aldosterone system inhibitors aDefined as medication prescribed within ±3 months of the index date bACE inhibitors included ramipril, lisinopril, enalapril maleate and captopril cARBs included candesartan cilexetil, losartan potassium and valsartan dMRAs included spironolactone and eplerenone
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us